What we know about upcoming news articles
Upcoming News Article
Kroll Restructuring Administration formerly Known as Prime Clerk
Kroll Restructuring Administration, formerly known as Prime Clerk, collects your email for the sole purpose of providing you with updates on the Chapter 11 bankruptcy case of Clovis Oncology, Inc. (the "Debtor").
Clovis Oncology filed for Chapter 11 bankruptcy protection on December 12, 2022. The Debtor is a biopharmaceutical company that focuses on the development and commercialization of cancer therapies.
The Debtor has voluntarily initiated a Chapter 11 bankruptcy case in the United States Bankruptcy Court for the District of Delaware. The Debtor is seeking to sell its experimental cancer drug, rociletinib, to raise funds to pay its creditors.
The Debtor has filed a motion with the Court seeking approval to sell its experimental cancer drug, rociletinib, to a third party. The sale of rociletinib is expected to be completed by the end of the year.
The Debtor has also filed a motion with the Court seeking approval to distribute a portion of its cash proceeds from the sale of rociletinib to its creditors.
Komentar